What is the cost of kisqali?

What determines the monthly price of Kisqali?
The wholesale acquisition cost for Kisqali is roughly $14,000 for a 28-day supply of the 600 mg dose, though actual out-of-pocket expense varies by insurance coverage, copay assistance programs, and pharmacy.

How do patient assistance programs affect what people pay?
Novartis offers the Kisqali Patient Assistance Program for uninsured or underinsured patients who meet income guidelines; eligible individuals may receive the drug at no cost. Separate copay savings cards can lower monthly costs to as little as $0 for commercially insured patients.

When does Kisqali’s patent protection end?
The key U.S. patents listed in the Orange Book expire between 2027 and 2031, with some formulation patents extending into the mid-2030s. Generic entry is unlikely before those dates unless earlier litigation or settlements occur.

Are biosimilars or generics already available?
No. Kisqali (ribociclib) remains a single-source branded product; no FDA-approved generic or biosimilar versions are on the market as of 2024.

How does Kisqali’s price compare with other CDK4/6 inhibitors?
Verzenio (abemaciclib) carries a similar list price of about $13,500 per month, while Ibrance (palbociclib) is closer to $15,000. Net prices after rebates and discounts are lower for all three and often comparable once payers negotiate.

Where can current pricing and patent details be checked?
DrugPatentWatch.com maintains up-to-date records on Kisqali’s patents, exclusivity periods, and pricing trends.